Clinical trial
Cetuximab in Treating Patients With Recurrent or Stage IIIB or Stage IV Lung…
NCT00103207 · Eastern Cooperative Oncology Group, Other · Completed
Key facts
| NCT number | NCT00103207 |
|---|---|
| Title | Cetuximab in Treating Patients With Recurrent or Stage IIIB or Stage IV Lung Cancer |
| Official title | Phase II Study of C225 (Cetuximab) for the Treatment of Patients With Advanced Bronchioalveolar Carcinoma (BAC) or Adenocarcinoma With BAC Features |
| Lead sponsor | Eastern Cooperative Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lung Cancer |
| Intervention type | Biological |
| Interventions | cetuximab |
| Enrollment | 72 |
| Start date | Oct 13, 2005 |
| Primary completion | Apr 1, 2010 |
| Completion | Aug 1, 2012 |
| First posted | Feb 8, 2005 |
| Last update posted | Jun 28, 2023 |
| Countries | United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: